Rational design of true hirudin mimetics: Synthesis and characterization of multisite-directed α-thrombin inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages 2008-2017

  Lombardi, Angela ^a   Nastri, Flavia ^a   Della Morte, Rossella ^b   Rossi, Armando ^c   De Rosa, Alfredo ^c   Staiano, Norma ^b   Pedone, Carlo ^a   Pavone, Vincenzo ^a  

^a Ctro Interdipartimentale Ric su P   (Italy)

^b Dipto Biochim Biotecnologie M   (Italy)

^c Development Biotechnology Processes   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIRUDIN DERIVATIVE; HIRUNORM IV; HIRUNORM V; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

AMIDES; AMINO ACID SEQUENCE; BLOOD COAGULATION; CATALYSIS; HIRUDINS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; THROMBIN;

EID: 0029984910     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950898g     Document Type: Article

References (64)

1. R, retention time; aPTT, activated partial thromboplastin time; PT, prothrombin time; TT, thromboplastin time; BSA, bovine serum albumine; ATU, antithrombin units.
2. (a) Fenton, J. W., II. Thrombin. Ann. N. Y. Acad. Sci. 1986, 485, 5-15.
3. (b) Fenton, J. W., II; Ofosu, F. A.; Moon, D. G.; Maraganore, J. M. Thrombin structure and function: Why thrombin is the primary target for antithrombotics. Blood Coag. Fibrinol. 1991, 2, 69-75.
4. (c) Berliner, L. J., Ed. In Thrombin Structure and Function; Plenum Press: New York, 1992.
5. Fenton, J. W., II; Bing, D. H. Thrombin active-site regions. Semin. Thromb. Haemostasis 1986, 12, 200-208.
6. (a) Markwardt, F. Hirudin is an inhibitor of thrombin. Methods Enzymol. 1970, 19, 924-932.
7. (b) Walsmann, P.; Markwardt, F. Biochemische und pharmakologische aspekte des thrombininhibitors hirudin. Pharmazie 1981, 36, 653-660.
8. (c) Markwardt, F. The development of hirudin as an antithrombotic drug. Thrombosis Res. 1994, 74, 1-23.
9. α-acetylhirudin 45-65. FEBS Lett. 1987, 211, 10-16.
10. (b) Jakubowski, J. A.; Maraganore, J. M. Inhibition of coagulation and thrombin induced platelet activities by a synthetic dodecapeptide modeled on the carboxy terminus of hirudin. Blood 1990, 75, 399-406.
11. (c) Maraganore, J. M.; Bourdon, P.; Jablonski, J.; Ramachandran, K. L.; Fenton, J. W., II. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29, 7095-7101.
12. (d) Szewczuk, Z.; Gibbs, B. F.; Yue, S. Y.; Purisima, E.; Zdanov, A.; Cygler, M.; Konishi, Y. Design of a linker for trivalent thrombin inhibitors: interaction of the main chain of the linker with thrombin. Biochemistry 1993, 32, 3396-3404.
13. (e) Tsuda, Y.; Cygler, M.; Gibbs, B. F.; Pedyczac, A.; Féthière, J.; Yue, S. Y.; Konishi, Y. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors. Biochemistry 1994, 33, 14443-14451.
14. Stone, S. R.; Hofsteenge, J. Kinetic of the inhibition of thrombin by hirudin. Biochemistry 1986, 25, 4622-4628.
15. Krstenansky, J. L.; Owen, T. J.; Yates, M. T.; Mao, S. J. T. Anticoagulant peptides: nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site of thrombin. J. Med. Chem. 1987, 30, 1688-1691.
16. (a) Rydel, T. J.; Tulinsky, A.; Bode, W.; Huber, R. Refined structure of the hirudin-thrombin complex. J. Mol. Biol. 1991, 221, 583-601.
17. (b) Grütter, M. G.; Priestle, J. P.; Rahuel, J.; Grossenbacher, H.; Bode, W.; Hofsteenge, J.; Stone, S. R. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J. 1990, 9, 2361-2365.
18. (c) Priestle, J. P.; Rahuel, J.; Rink, H.; Tones, M.; Grütter, M. G. Changes in interaction in complexes of hirudin derivatives and human α-thrombin due to different crystal forms. Protein Sci. 1993, 2, 1630-1642.
19. Skrzypczak-Jankun, E.; Carperos, V. E.; Ravichandran, K. G.; Tulinsky, A.; Westbrook, M.; Maraganore, J. M. Structure of hirugen and hirulog 1 complexes of α-thrombin. J. Mol. Biol. 1991, 221, 1379-1393
20. Zdanov, A.; Wu, S.; DiMaio, J.; Konishi, Y.; Li, Y.; Wu, X.; Edwards, B. F. P.; Martin, P. D.; Cygler, M. Crystal structure of the complex of human α-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6. Proteins: Struct., Funct., Genet. 1993, 17, 252-265.
21. (a) Huber, R.; Bode, W. Structural basis of the activation and action of trypsin. Acc. Chem. Res. 1978, 11, 114-122.
22. (b) Read, R. J.; James, M. N. G. Introduction of protein inhibitors: X-ray crystallography. In Proteinase inhibitors; Elsevier: Amsterdam, 1986; pp 301-336.
23. (a) Iwanowicz, E. J.; Lau, W. F.; Lin, J.; Roberts, D. G. M.; Seiler, S. M. Retro-binding tripeptide thrombin active-site inhibitors: discovery, synthesis, and molecular modeling. J. Med. Chem. 1994, 37, 2122-2124.
24. (b) Tabernero, L.; Chang, C. Y. Y.; Ohringer, S. L.; Lau, W. F.; Iwanowcz, E. J.; Han, W.; Wang, T. C.; Seiler, S. M.; Roberts, D. G. M.; Sack, J. S. Structure of a retro-binding peptide inhibitor complexed with human α-thrombin. J. Mol. Biol. 1995, 246, 14-20.
25. Stubbs, T. S.; Bode, W. A player of many parts: the spotlight falls on thrombin structure. Thrombosis Res. 1993, 69, 1-58.
26. Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. The refined 1.9 A crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg-chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8, 3467-3475.
27. Powers, J. C.; Kam, C.-M. Synthetic substrates and inhibitors of thrombin. In Thrombin: Structure and Function; Plenum Press: New York, 1992; pp 117-158.
28. Steiner, V.; Knecht, R.; Börnsen, O.; Gassmann, E.; Stone, S. R.; Raschdorf, F.; Schlaeppi, J.; Maschler, R. Primary structure and function of novel O-glycosylated hirudins from the leech Hirudinaria menillensis. Biochemistry 1992, 31, 2294-2298.
29. Lazar, J. B.; Winant, R. C.; Johnson, P. H. Hirudin: Amino-terminal residues play a major role in the interaction with thrombin. J. Biol. Chem. 1991, 266, 685-688.
30. Betz, A.; Hosteenge, J.; Stone, S. R. Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin. Biochemistry 1992, 31, 4557-4562.
31. (a) Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tezuka, T.; Tonomura, S.; Okamoto, S.; Hijikata, A. Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of Nα-substituted L-arginine. J. Med. Chem. 1980, 23, 1293-1299.
32. (b) Kaiser, B.; Hauptman, J.; Markwardt, F. Studies of the pharmacodynamics of synthetic thrombin inhibitors of the basically substituted Na-aryl-sulfonylated phenylalanine amide type. Pharmazie 1987, 42, 119-121.
33. (c) Claeson, G.; Cheng, L.; Chino, N.; Deadman, J.; Elgendy, S.; Kakkar, V. V.; Scully, M. F.; Phillipp, M.; Lundin, R.; Mattson, C. Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences. In Peptides: Chemistry and Biology. Proceedings of the 12th American Peptide Symposium; ESCOM Science Publishers B. V.: Leiden, The Netherlands, 1992; pp 824-825.
34. (a) Adzhubei, A. A.; Eisenmenger, F.; Tumanyan, V. G.; Zinke, M.; Brodzinski, S.; Esipova, N. G. Third type of secondary structure: non cooperative mobile conformation, protein data bank analysis. Biochem. Biophys. Res. Commun. 1987, 146, 934-938.
35. (b) Swindells, M. B.; MacArthur, M. W.; Thornton, J. M. Intrinsic φ, ψ propensities of amino acids, derived from coil regions of known structures. Nature Struct. Biol. 1995, 2, 596-603.
36. Di Blasio, B.; Lombardi, A.; Yang, X.; Pedone, C.; Pavone, V. β-Alanyl-β-alanine in cyclic β-turned peptides. Biopolymers 1991, 31, 1181-1188.
37. Yue, S.-Y.; DiMaio, J.; Szewczuk, Z.; Purisima, E. O.; Ni, F.; Konishi, Y. Characterization of the interaction of a bifunctional inhibitor with α-thrombin by molecular modeling and peptide synthesis. Protein Eng. 1992, 5, 77-85.
38. Dennis, S.; Wallace, A.; Hofsteenge, J.; Stone, S. R. Use of fragments of hirudin to investigate thrombin-hirudin interaction. Eur. J. Biochem. 1990, 188, 61-66.
39. Barany, G.; Merrifield, R. B. Solid-Phase Peptide Synthesis. In The Peptides: Analysis, Synthesis, Biology; Gross, E., Meienhofer, J., Eds.; Academic Press: New York, 1980; Vol. 2, pp 199-208.
40. Krstenansky, J. L.; Broersma, R. J.; Owen, T. J.; Payne, M. H.; Yates, M. T.; Mao, S. J. Development of MDL 28,050, a small antithrombin agent based on a functional domain of the leech protein, hirudin. Thromb. Haemostasis 1990, 63, 208-214.
41. (a) Szewczuk, Z.; Gibbs, B. F.; Yue, S.-Y.; Purisima, E. O.; Konishi, Y. Conformationally restricted thrombin inhibitors resistant to proteoplytic digestion. Biochemistry 1992, 31, 9132-9140.
42. (b) Krstenansky, J. L.; Owen, T. J.; Yates, M. T.; Mao, S. J. T. Design, synthesis and antithrombin activity for conformationally restricted analogs of peptide anticoagulants based on the C-terminal region of the leech peptide, hirudin. Biochim. Biophys. Acta 1988, 957, 53-59.
43. (c) Ning, Q.; Ripoll, D. R.; Szewczuk, Z.; Konishi, Y.; Ni, F. Thrombin-bound conformation of a cyclic anticoagulant peptide using transferred nuclear Overhauser effect (NOE), distance geometry, and NOE simulations. Biopolymers 1994, 34, 1125-1137.
44. 10-helix at atomic resolution. J. Mol. Biol. 1990, 214, 633-635.
45. (a) Knadler, M. P.; Ackermann, B. L.; Coutant, J. E.; Hurst, G. H. Metabolism of the anticoagulant peptide, MDL 28,050, in rats. Drug Metab. Dispos. 1992, 20, 89-95.
46. (b) Chang, J.-Y. The functional domain of hirudin, a thrombin-specific inhibitor. FEBS Lett. 1983, 164, 307-313.
47. (c) Chang, J.-Y. Production, properties, and thrombin inhibitory mechanism of hirudin amino-terminal core fragments. J. Biol. Chem. 1990, 265, 22159-22166.
48. Caciagli, V.; Cardinali, F.; Bonelli, F.; Lombardi, P. Large-scale solid-phase continuous-flow preparation of 26-mer peptide thrombin inhibitor. In Innovation and Perspectives in Solid Phase Synthesis; Epton, R., Ed.; 1995, in press.
49. Cappiello, M.; Vilardo, P. G.; Lippi, A.; Staiano, N.; Lombardi, A.; Del Corso, Z.; Mura, U. Kinetics of human thrombin inhibition by two novel peptide inhibitors hirunorm IV and hirunorm V. Unpublished results.
50. Witting, J. I.; Bourdon, P.; Brezniak, D.; Maraganore, J. M.; Fenton, J. W. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem. J. 1992, 283, 737-743.
51. Witting, J. I.; Bourdon, P.; Maraganore, J. M.; Fenton, J. W., II. Hirulog-1 and B-2 thrombin specificity. Biochem. J. 1992, 287, 663-664.
52. Cirillo, R.; Lippi, A.; Subissi, A.; Staiano N.; Della Morte, R.; Agnelli, G.; Criscuoli, M. Experimental Pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor. Unpublished results.
53. Maraganore, J. M.; Chao, B.; Joseph, M. L.; Jablonsky, J.; Ramachandran, K. L. Anticoagulant activity of synthetic hirudin peptides. J. Biol. Chem. 1989, 264, 8692-8698.
54. (a) Abola, E. E.; Bernstein, F. C.; Bryant, S. H.; Koetzle, T. F.; Weng, J. In Data Commission of the International Union of Crystallography; Allen, F. H., Bergerhoff, G., Sievers, R., Eds.; Bonn-Cambridge-Chester, 1987, pp 107-132.
55. (b) Bernstein, F. c.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F. Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. (version of January 1992) J. Mol. Biol. 1987, 112, 535-542.
56. Biosym Technologies. Insight II User guide, version 2.3.0, San Diego, 1993.
57. (a) Lifson, S.; Hagler, A. T.; Dauber, P. Consistent force field studies of intermolecular forces in hydrogen bonded crystals. 1. carboxylic acids, amides and the C-OH hydrogen bonds. J. Am. Chem. Soc. 1979, 101, 5111-5121.
58. (b) Hagler, A. T.; Dauber, P.; Lifson, S. Consistent force field studies of intermolecular forces in hydrogen bonded crystals. 2. a banchmark for the objective comparison of alternative force field. J. Am. Chem. Soc. 1979, 101, 5131-5141.
59. (c) Hagler, A. T.; Lifson, S.; Dauber, P. Consistent force field studies of intermolecular forces in hydrogen bonded crystals. 3. the C=OH-O hydrogen bond and the analysis of the energetics and packing of carboxylic acids. J. Am. Chem. Soc. 1979, 101, 5122-5130.
60. Frérot, E.; Coste, J.; Pantaloni, A.; Dufour, M. N.; Jouin, P. PyBOP and PyBroP: two reagents for the difficult coupling of the α,α-dialkyl amino acid, Aib. Tetrahedron 1991, 47, 259-270.
61. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
62. Sakakibara, S. The use of hydrogen fluoride in peptide chemistry. In Chemistry and Biochemistry of Amino Acids, Peptides and Proteins; Weinstein, B., Ed.; Dekker: New York, 1971.
63. Fenton, J. W., II; Fosco, M. J.; Stackrow, A. B.; Aronson, D. L.; Young, A. M.; Finlayson, J. S. Human thrombosis. Production, evaluation and properties of α-thrombin. J. Biol. Chem. 1977, 252, 3587-3598.
64. Segel, I. H. In Enzyme Kinetics; J. Wiley & Sons: New York, 1975.